Loading institutional data...
Loading institutional data...
Held by 359 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81 · book equity (no price)
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $25M buybacks = $25M returned on $209M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 22%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $589.0M 100.0% | $491.7M 100.0% | $398.2M 100.0% | $214.2M 100.0% | $140.8M 100.0% | $119.1M 100.0% | $102.3M 100.0% | $500K 100.0% | $0 | $0 |
| Cost of Revenue | $87.3M 14.8% | $68.8M 14.0% | $52.0M 13.1% | $34.4M 16.1% | $21.9M 15.5% | $17.0M 14.3% | $14.8M 14.4% | — | — | — |
| Research & Development | $12.7M 2.2% | $12.6M 2.6% | $93.2M 23.4% | $19.8M 9.2% | $16.9M 12.0% | $16.5M 13.9% | $18.8M 18.4% | $19.9M 3983.8% | $11.4M | $11.4M |
| Selling, General & Admin | $193.8M 32.9% | $177.7M 36.1% | $133.7M 33.6% | $57.1M 26.6% | $49.6M 35.2% | $44.2M 37.1% | $36.9M 36.0% | $15.9M 3175.2% | $7.3M | $7.9M |
| Total Operating Expenses | $206.5M 35.1% | $190.4M 38.7% | $226.9M 57.0% | $76.9M 35.9% | — | — | — | $35.8M 7159.0% | $18.7M | $19.3M |
| Operating Income | $257.8M 43.8% | $195.1M 39.7% | $86.8M 21.8% | $101.8M 47.5% | $52.4M 37.2% | $41.3M 34.7% | $31.8M 31.1% | -$35.3M -7059.0% | -$18.7M | -$19.3M |
| Other Income (Expense), net | $25.7M 4.4% | $21.1M 4.3% | $7.7M 1.9% | $2.9M 1.3% | $282K 0.2% | $587K 0.5% | $1.6M 1.6% | $1.3M 258.3% | $454K | $322K |
| Pretax Income | $283.5M 48.1% | $216.3M 44.0% | $94.5M 23.7% | $104.7M 48.9% | $52.7M 37.4% | $41.9M 35.2% | $33.4M 32.7% | -$34.0M -6800.7% | -$18.4M | -$18.1M |
| Income Tax Expense | $69.2M 11.7% | $52.4M 10.7% | $23.1M 5.8% | $21.6M 10.1% | $13.2M 9.4% | -$33.1M -27.8% | $1.5M 1.5% | $0 0.0% | $0 | $0 |
| Net Income | $214.3M 36.4% | $163.9M 33.3% | $71.4M 17.9% | $83.1M 38.8% | $39.5M 28.0% | $75.0M 63.0% | $31.9M 31.2% | -$34.0M -6800.7% | -$18.4M | -$18.1M |
| Per Share | ||||||||||
| EPS (Basic) | $1.75 | $1.38 | $0.67 | $0.80 | $0.38 | $0.72 | $0.31 | $-0.33 | — | — |
| EPS (Diluted) | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 | $0.71 | $0.30 | $-0.33 | — | — |
| Weighted Avg Shares (Basic) | 122.3M | 118.5M | 106.3M | 103.4M | 103.4M | 103.5M | 102.9M | 102.6M | — | — |
| Weighted Avg Shares (Diluted) | 127.3M | 124.9M | 113.8M | 111.4M | 107.8M | 106.2M | 106.0M | 102.6M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| CPRX | — | — | — | — | 19.8% | 85.2% | 36.4% | 22.5% | 22.5% | — | 359 |
Peers = companies sharing CPRX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
No current price collected.
No material risks flagged.
Where each multiple sits in its own 14-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.6× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | 14.4 | 14.3 | 15.5 | 16.1 | 13.1 | 14.0 | 14.8 |
| R&D | 3983.8 | 18.4 | 13.9 | 12.0 | 9.2 | 23.4 | 2.6 | 2.2 |
| SG&A | 3175.2 | 36.0 | 37.1 | 35.2 | 26.6 | 33.6 | 36.1 | 32.9 |
| Operating Income | -7059.0 | 31.1 | 34.7 | 37.2 | 47.5 | 21.8 | 39.7 | 43.8 |
| Income Tax | 0.0 | 1.5 | -27.8 | 9.4 | 10.1 | 5.8 | 10.7 | 11.7 |
| Net Income | -6800.7 | 31.2 | 63.0 | 28.0 | 38.8 | 17.9 | 33.3 | 36.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CPRX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.